Table 2. IHC analysis of AnxA6 expression in PDAC (N=57) using MAb 9E1 and correlation with clinicopathological features.
|
AnxA6 |
||||
|---|---|---|---|---|
| Clinicopathological feature | No. of positive tumours | High immunoreactivity (IHC score 4–8) | Low immunoreactivity (IHC score 1–4) | P-value |
| Overall | 57 | 36 (63.1%) | 21 (36.84%) | |
| Sex | ||||
| Male | 22/36 (61.1%) | 14/21 (66.66%) | 0.7452 | |
| Female | 14/36 (38.8%) | 7/21 (33.33%) | ||
| Age | ||||
| <65 | 19/36 (52.77%) | 12/21 (57.1%) | 0.9022 | |
| >65 | 17/36 (47.3%) | 9/21 (42.85%) | ||
| Tumour size | ||||
| <4 cm | 29/36 (80.55%) | 15/21 (71.4%) | 0.4332 | |
| > 4 cm | 7/36 (19.44%) | 5/21 (23.8%) | ||
| Histological grade | ||||
| Grade I | 3/36 (8.33%) | 2/21 (9.52%) | 0.3624 | |
| Grade II | 25/36 (69.44%) | 12/21 (57.1%) | ||
| Grade III | 8/36 (22.22%) | 7/21 (33.33%) | ||
| Node status | ||||
| N0 | 10/36 (27.77%) | 8/21 (38%) | 0.4234 | |
| N1 | 26/36 (72.2%) | 13/21 (61.9%) | ||
| Lymphovascular invasion (LVI) | ||||
| Present | 24/36 (66.66%) | 13/21 (61.9%) | 0.7223 | |
| Absent | 12/36 (33.33%) | 8/21 (38%) | ||
| Perineural invasion (PNI) | ||||
| Present | 28/36 (77.7%) | 2/21 (9.52%) | < 0.0001 | |
| Absent | 8/36 (22.22%) | 19/21 (90.4%) | ||
| Tumour budding | ||||
| Present (n=13) | 11/13 (84.6%) | 2/13 (15.4%) | 0.0827 | |
| Absent (n=20) | 11/20 (55%) | 9/20 (45%) | ||
| Unknown (n=24) | — | — | ||
Abbreviations: AnxA6= annexin a6; IHC=immunohistochemistry; MAb=monoclonal antibody; PDAC= pancreatic adenocarcinoma. Bold values indicate statistical significance.